HOME >> MEDICINE >> NEWS
Yale prostate cancer study shows newer implant therapy has fewer side-effects, could lead to better treatment outcomes

New Haven, Conn. -- A Yale study of complication rates from two radiation implant therapies for prostate cancer shows that the newer therapy, Palladium-103, has fewer long-term side effects than Iodine-125, an older, more commonly prescribed therapy.

"While both implants were extraordinarily successful at preventing major long-term complications, Palladium-103 was superior to Iodine-125 in preventing moderate long-term complications by 13 percent," said Richard Peschel, M.D., professor of therapeutic radiology at Yale School of Medicine. "Our study is the first to compare prostate cancer implant therapies, and the results could lead to improved outcomes for patients."

In the seven-year study, Peschel and his team also found that the minimum dose for Palladium-103 could be increased without increasing side effects. This increased dose has the potential for improving cure rates, Peschel says.

Published in the Oct. 29 issue of Radiation Oncology Investigations: Clinical and Basic Research, the findings are significant for men facing a treatment decision for prostate cancer.

When diagnosed with prostate cancer, most men are presented with two treatment options: radical surgery and implant therapy, which involves placing 75 to 100 small radioactive seeds throughout the prostate using a one-time, minimally invasive procedure. Implant therapy is an increasingly popular choice because it is a cheaper, simpler out-patient procedure that involves far less recovery time, a lower complication rate and cure rates that are equivalent to radical surgery.

For 10 to 15 years, Iodine-125 was the most frequently prescribed implant treatment, but newer therapies have emerged, including Palladium-103. Prostate cancer implant programs using either Iodine-125 or Palladium-103 radioactive seeds have been extremely successful in treating early prostate cancer. About 30,000 prostate implants will be performed in the United States in the year 2000.

The resear
'"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
28-Oct-1999


Page: 1 2

Related medicine news :

1. Hormonal treatment improves survival in high-risk prostate cancer patients
2. Cultural and social factors influence prostate cancer treatment
3. Earlier use of prostate cancer vaccines urged by Hopkins scientists
4. Tumor-targeted immune cells cure prostate cancer in mice without causing systemic immune suppression
5. Men more likely to get screened for prostate cancer than colon cancer, U-M study finds
6. Mayo Clinic identifies key cellular process in prostate and other cancers
7. Obesity may affect accuracy of prostate screening
8. More precise radiation therapy lets prostate cancer patients avoid erectile dysfunction
9. Combining hormones with external, internal radiation helps high risk prostate cancer patients
10. Silent risk of osteoporosis in men with prostate cancer
11. NIH launches new study to compare prostate surgery and drugs

Post Your Comments:
(Date:3/31/2015)... Burns Engineering announces 3-Day Quick Ship on S01 ... Beverage, Pharmaceutical and Biotech markets. These field proven sensors conform ... now available as part of Burns’ Quick Ship Program to ... and S03 with 1/8” and 1/4” diameters respectively are ... process lines 1/4” and larger. Sensors are available in ...
(Date:3/31/2015)... The report “Coagulation/Hemostasis Analyzer Market ... Type (APTT, Prothrombin Time/INR, D-Dimer, Fibrinogen), Technology (Mechanical, ... analyzes and studies the major market drivers, restraints, ... and the Rest of the world (RoW). ... to reach $3.58 billion by 2019 from $2.4 ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 ... that specializes in providing online solutions to ... today it has achieved full accreditation for ... Network Accreditation Program (HNAP) from the Electronic ... EHNAC’s HNAP accreditation runs in two-year increments ...
(Date:3/31/2015)... March 31, 2015 Diane Blackburn-Zambetti ... at the Mesothelioma Applied Research Foundation (Meso Foundation). ... and Your Health” at the BoRit Asbestos Superfund ... April. This program will discuss anatomy, six types ... asbestos diseases, symptoms, treatments, prevention and proper communication ...
(Date:3/31/2015)... Nashville, TN (PRWEB) March 31, 2015 ... TN welcomes warmer temperatures and sunshine; however, it's important to ... irreversible eye damage. Experts say more than 90 ... a few precautions and wearing safety glasses. Dr. Shofner shares ... damage this season. , 1) Yard Work. While using a ...
Breaking Medicine News(10 mins):Health News:Burns Engineering Now Offers 3-Day Quick Ship on Sanitary RTDs and Thermocouples 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 3Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 4Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 2Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 3Health News:Mesothelioma Foundation to speak at BoRit Asbestos Superfund Citizen Advisory Group Meeting 2Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 2Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 3Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 4
(Date:3/31/2015)... March 31, 2015  On May 2, 2015 ... in Santa Monica, CA ... Therapies for Malignant Pleural Mesothelioma (MPM), a rare ... asbestos and commonly affects the lining of the ... UCLA and the Pacific Mesothelioma Center (PMC). ...
(Date:3/31/2015)... 2015  InMed Pharmaceuticals Inc. ("InMed") (CSE: IN; ... specializes in developing safer, more effective cannabis-based therapies, ... Anderson , Ph.D., to its Scientific Advisory Board.  ... brings significant drug discovery and development expertise to ... organic chemist by training with more than 30 ...
(Date:3/31/2015)... TEMPLE, Texas , March 31, 2015   ... its operational transformation is complete and the company has ... guidelines. "Our goal as a company is ... CEO Travis Leeah . "Meeting the new regulations ... dedicated staff. We,re embracing the future of our industry, ...
Breaking Medicine Technology:Cutting-Edge Research to Be Presented at 5th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma in Santa Monica 2Cutting-Edge Research to Be Presented at 5th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma in Santa Monica 3Cutting-Edge Research to Be Presented at 5th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma in Santa Monica 4InMed Pharmaceuticals Strengthens Scientific Advisory Board 2InMed Pharmaceuticals Strengthens Scientific Advisory Board 3InMed Pharmaceuticals Strengthens Scientific Advisory Board 4Unique Pharmaceuticals Launches Sterile Operations under New Federal Guidance 2Unique Pharmaceuticals Launches Sterile Operations under New Federal Guidance 3
Cached News: